dc.creator | Maldonado y Aibar, María Dolores | es |
dc.creator | Romero Aibar, J. | es |
dc.date.accessioned | 2022-11-09T15:09:12Z | |
dc.date.available | 2022-11-09T15:09:12Z | |
dc.date.issued | 2021-12 | |
dc.identifier.citation | Maldonado y Aibar, M.D. y Romero Aibar, J. (2021). The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus. Brain, Behavior, & Immunity - Health, 18, 100381. https://doi.org/10.1016/j.bbih.2021.100381. | |
dc.identifier.issn | 2666-3546 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139187 | |
dc.description.abstract | Background
To prevent the invasion and transmission of SARS-CoV-2, mRNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been developed. The European Medicines Agency (EMA) authorized the use of the anti-SARS-CoV-2 vaccine in January 2021, the date on which the vaccination program began in Spain and across Europe. The aim of this study is to monitor the safety of anti-SARS-CoV-2 vaccines and report any cases of undesirable effects that have occurred, that are not included in the health profile of mRNA-based vaccines for commercialisation in humans. Furthermore, a brief review is given of the mechanism of action of the anti-SARS-CoV-2 vaccine on the host's immune system in triggering the reactivation of the herpes varicella-zoster infection.
Methods
Follow-up of patients under the care of the southern health district of Seville of the SAS (Andalusian Health Service) during the Spanish state of alarm over the COVID-19 pandemic.
Results
Two patients, a 79-year-old man and a 56-year-old woman, are reported who, after 4 and 16 days respectively of receiving the Pfizer-BNT162b2 vaccine against SARS-CoV-2, presented a state of reactivation of herpes varicella-zoster virus (VZV).
Discussion
The immunosenescence of the reported patients, together with the immunomodulation generated by administering the anti-SARS-CoV-2 vaccines, that depress certain cell subpopulations, could explain the awakening of VZV latency. | es |
dc.format | application/pdf | es |
dc.format.extent | 5 p. | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.relation.ispartof | Brain, Behavior, & Immunity - Health, 18, 100381. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | The anti-SARS-CoV-2 vaccines | es |
dc.subject | mRNA-based vaccines | es |
dc.subject | Herpes zoster infection | es |
dc.subject | Immune system | es |
dc.title | The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Bioquímica Médica y Biología Molecular e Inmunología | es |
dc.relation.projectID | BFU2017-85832-R | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S2666354621001848?via%3Dihub | es |
dc.identifier.doi | 10.1016/j.bbih.2021.100381 | es |
dc.journaltitle | Brain, Behavior, & Immunity - Health | es |
dc.publication.volumen | 18 | es |
dc.publication.initialPage | 100381 | es |
dc.contributor.funder | Ministerio de Economia, Industria y Competitividad (MINECO). España | es |